Cargando…
The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
BACKGROUND: Early diagnosis decreases the mortality of hepatocellular carcinoma (HCC). We aimed to investigate the usefulness of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in the diagnosis of primary and metastatic HCC. METHODS: One hundred and twenty patients with primary HCC (PHC), 115 wit...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246383/ https://www.ncbi.nlm.nih.gov/pubmed/31821607 http://dx.doi.org/10.1002/jcla.23158 |
_version_ | 1783537933168410624 |
---|---|
author | Qi, Famei Zhou, Aihua Yan, Li Yuan, Xiumei Wang, Danni Chang, Ruoyun Zhang, Yujun Shi, Funa Han, Xiaomei Hou, Jinxia Wei, Lianhua Zhang, Xu |
author_facet | Qi, Famei Zhou, Aihua Yan, Li Yuan, Xiumei Wang, Danni Chang, Ruoyun Zhang, Yujun Shi, Funa Han, Xiaomei Hou, Jinxia Wei, Lianhua Zhang, Xu |
author_sort | Qi, Famei |
collection | PubMed |
description | BACKGROUND: Early diagnosis decreases the mortality of hepatocellular carcinoma (HCC). We aimed to investigate the usefulness of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in the diagnosis of primary and metastatic HCC. METHODS: One hundred and twenty patients with primary HCC (PHC), 115 with metastatic HCC (MHC), 89 with chronic liver disease (CLD), and 116 healthy volunteers were included. The diagnostic values of each marker and their combinations for HCC diagnosis were represented by ROC curve analyses. RESULTS: PIVKA‐II, AFP, and AFP‐L3 levels in PHC group were higher than that in normal control, CLD, and MHC groups. CEA levels in MHC group were higher than that in the other three groups. When the four markers were analyzed individually, PIVKA‐II showed the highest positive rate in PHC group (76.7%) and CEA showed the highest positive rate in MHC group (69.6%). PIVKA‐ II showed the largest area under ROC curve (AUC = 0.835) to discriminate PHC group from CLD group. Combined PIVKA‐II with AFP‐L3 increased the AUC to 0.910. CEA showed the highest AUC (0.849) to discriminate MHC group from CLD group. Combined CEA with PIVKA‐II increased the AUC to 0.866. AFP‐L3 alone showed the highest AUC (0.890) to discriminate MHC group from PHC group. Combined PIVKA‐II with AFP‐L3, and CEA increased the AUC to 0.957. CONCLUSION: PIVKA‐II, AFP‐L3, AFP, and CEA are effective biomarkers for the diagnosis of PHC and MHC. Their combinations could improve the diagnostic performance compared with each marker used alone in detecting PHC and MHC. |
format | Online Article Text |
id | pubmed-7246383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72463832020-06-01 The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma Qi, Famei Zhou, Aihua Yan, Li Yuan, Xiumei Wang, Danni Chang, Ruoyun Zhang, Yujun Shi, Funa Han, Xiaomei Hou, Jinxia Wei, Lianhua Zhang, Xu J Clin Lab Anal Research Articles BACKGROUND: Early diagnosis decreases the mortality of hepatocellular carcinoma (HCC). We aimed to investigate the usefulness of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in the diagnosis of primary and metastatic HCC. METHODS: One hundred and twenty patients with primary HCC (PHC), 115 with metastatic HCC (MHC), 89 with chronic liver disease (CLD), and 116 healthy volunteers were included. The diagnostic values of each marker and their combinations for HCC diagnosis were represented by ROC curve analyses. RESULTS: PIVKA‐II, AFP, and AFP‐L3 levels in PHC group were higher than that in normal control, CLD, and MHC groups. CEA levels in MHC group were higher than that in the other three groups. When the four markers were analyzed individually, PIVKA‐II showed the highest positive rate in PHC group (76.7%) and CEA showed the highest positive rate in MHC group (69.6%). PIVKA‐ II showed the largest area under ROC curve (AUC = 0.835) to discriminate PHC group from CLD group. Combined PIVKA‐II with AFP‐L3 increased the AUC to 0.910. CEA showed the highest AUC (0.849) to discriminate MHC group from CLD group. Combined CEA with PIVKA‐II increased the AUC to 0.866. AFP‐L3 alone showed the highest AUC (0.890) to discriminate MHC group from PHC group. Combined PIVKA‐II with AFP‐L3, and CEA increased the AUC to 0.957. CONCLUSION: PIVKA‐II, AFP‐L3, AFP, and CEA are effective biomarkers for the diagnosis of PHC and MHC. Their combinations could improve the diagnostic performance compared with each marker used alone in detecting PHC and MHC. John Wiley and Sons Inc. 2019-12-10 /pmc/articles/PMC7246383/ /pubmed/31821607 http://dx.doi.org/10.1002/jcla.23158 Text en © 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Qi, Famei Zhou, Aihua Yan, Li Yuan, Xiumei Wang, Danni Chang, Ruoyun Zhang, Yujun Shi, Funa Han, Xiaomei Hou, Jinxia Wei, Lianhua Zhang, Xu The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma |
title | The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma |
title_full | The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma |
title_fullStr | The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma |
title_full_unstemmed | The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma |
title_short | The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma |
title_sort | diagnostic value of pivka‐ii, afp, afp‐l3, cea, and their combinations in primary and metastatic hepatocellular carcinoma |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246383/ https://www.ncbi.nlm.nih.gov/pubmed/31821607 http://dx.doi.org/10.1002/jcla.23158 |
work_keys_str_mv | AT qifamei thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT zhouaihua thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT yanli thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT yuanxiumei thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT wangdanni thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT changruoyun thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT zhangyujun thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT shifuna thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT hanxiaomei thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT houjinxia thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT weilianhua thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT zhangxu thediagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT qifamei diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT zhouaihua diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT yanli diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT yuanxiumei diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT wangdanni diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT changruoyun diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT zhangyujun diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT shifuna diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT hanxiaomei diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT houjinxia diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT weilianhua diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma AT zhangxu diagnosticvalueofpivkaiiafpafpl3ceaandtheircombinationsinprimaryandmetastatichepatocellularcarcinoma |